In a 2020 phase 2 randomized clinical trial involving patients with neovascular age-related macular degeneration, the mean change in best-corrected visual acuity was no different in patients given intravitreal faricimab (an anti–angiopoietin-2 and anti–vascular endothelial growth factor A monoclonal antibody) every 12 or 16 weeks vs ranibizumab every 4 weeks. This video provides a detailed summary of the trial background, methods, and findings. Faricimab is under evaluation in phase 3 clinical trials for its efficacy and safety in a broader population of patients with neovascular age-related macular degeneration. Click the Related Article link for the full clinical report.
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
You currently have no searches saved.
You currently have no courses saved.